VOLT-02 is a water-soluble conjugate of progesterone and a neurosteroid which is under development by Levolta Pharmaceuticals (formerly Voltarra Pharmaceuticals) for the treatment of traumatic brain injury, gynecological disorders, and menstrual disorders.[1] As of March 2017, it is in phase II clinical trials for these indications.[1] The chemical structure of VOLT-02 does not appear to have been released yet.[1]
| Clinical data | |
|---|---|
| Other names | Progesterone conjugate |
| Drug class | Progestogen; Neurosteroid |
| Identifiers | |
| CAS Number | |
See also
editReferences
edit- ^ a b c "Progesterone conjugate - Levolta Pharmaceuticals - AdisInsight". adisinsight.springer.com.
External links
edit
 | This article about a steroid is a stub. You can help Wikipedia by expanding it. |
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |